糖脉康治疗早期糖尿病肾病疗效观察及对患者血清超氧化物岐化酶、过氧化氢酶、丙二醛水平的影响

Clinical efficacy of tangmaikang for treating with early diabetic nephropathy and its impact on oxidative stress

目的 观察糖脉康治疗早期糖尿病肾病的临床疗效,并探讨其对患者血清超氧化物岐化酶（SOD）、过氧化氢酶（CAT）、丙二醛（MDA）水平的影响.方法 选择94例早期糖尿病肾病患者,按数字表法随机平均分为两组,对照组（47例）给予常规治疗,观察组（47例）在常规治疗的基础上加用糖脉康治疗,两组均治疗8周.观察两组临床治疗疗效,同时观察氧化应激指标SOD、CAT、MDA水平变化.结果 观察组治疗总有效率为91.5％,显著高于对照组的68.1％（x2=57.31,P＜0.05）；观察组SOD显著升高至（81.2±8.9）μU/L,CAT显著升高至（27.3±2.5）μU/L,MDA显著降低至（4.9±0.5）μmol/L,与对照组差异均有统计学意义（t=3.01、2.75、2.14,均P＜0.05）.结论 糖脉康治疗早期糖尿病肾病临床疗效确切,可能通过抑制氧化应激机制来发挥肾脏保护作用.

Objective To observe the clinical efficacy of Tangmaikang in the treatment of early diabetic nephropathy,and explore the impact of oxidative stress for patients.Methods 94 patients with early diabetic nephropathy were randomly divided into two groups,the control group （n =47） was treated with conventional therapy while the study group （n =47） was given Tangmaikang on the basis of the conventional group,all of the patients was treated for 8 weeks.After the end of treatment,the clinical efficacy and changes in oxidative stress indicators were evaluated.Results The total effective rate of the study group（91.5%） was significantly higher than that of the control group （68.1%）,there was statistically significant difference （x2 =57.31,P 〈0.05）.The serum superoxide dismutase （SOD） of the study group increased to （81.2 ± 8.9）μU/L,catalase （CAT） increased to （27.3 ± 2.5）μU/L,malondialdehyde（MDA） decreased to （4.9± 0.5）μmol/L,and there were statistically significant differences compared with the control group（t =3.01,2.75,2.14,all P 〈0.05）.Conclusion Tangmaikang in the treatment of early diabetic nephropathy has good effect,which plays a renoprotective effect on inhibiting oxidative stress.